Global Sjogren’s Syndrome Acids Market Reaches $302.5 Million in 2025 with 6.2% CAGR

Sjogren’s syndrome market was valued at $302.5 million in 2025 and is projected to reach $546.8 million by 2035, growing at a CAGR of 6.2% during the forecast period (2026-2035). Sjogren’s syndrome is a chronic autoimmune disorder characterized by lymphocytic infiltration of exocrine glands, leading to symptoms such as dry eyes, dry mouth, fatigue, and systemic complications. The market encompasses symptomatic and disease-modifying treatment options, including secretagogues, immunosuppressants, corticosteroids, biologics, and supportive therapies for ocular and oral dryness.

Browse the full report description of “Sjogren’s Syndrome Market Size, Share & Trends Analysis Report By Test (Blood Test, Eye Test, Imaging Test, and Biopsy), By Drug Type (Pilocarpine, Cyclosporine, Hydroxychloroquine, and Immunosuppressive Agents), and by Type (Primary Sjogren’s Syndrome, Secondary Sjogren’s Syndrome) Forecast Period, (2026-2035)” of https://www.omrglobal.com/industry-reports/sjogrens-syndrome-market

The market is experiencing steady global growth, driven by rising disease awareness, improved diagnostic rates, and increasing prevalence among aging populations, particularly women. Key trends shaping the Sjogren’s syndrome therapeutics landscape include growing research into targeted biologics and immune-modulating therapies, expansion of combination treatment approaches to manage systemic manifestations, and increased focus on personalized medicine based on disease severity and patient profiles. In addition, favorable regulatory pathways for orphan and autoimmune drugs, along with expanding clinical trial activity, are supporting long-term market expansion across major regions.

According to PMC and National Institutes of Health (NIH)/PubMed, Sjogren’s syndrome continues to present a substantial global health burden, with prevalence increasing awareness, diagnostic activity, and reliance on symptomatic treatments that influence the acids/therapeutic market dynamics.

Key Innovators Driving Sjogren’s Syndrome  Transformation

The key players in the sjogren’s syndrome  market include AbbVie Inc., Bausch + Lomb Corporation, F. Hoffmann-La Roche Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, among others. These companies are actively advancing the treatment landscape through investments in biologics, novel small-molecule therapies, and pipeline candidates targeting underlying autoimmune mechanisms, shaping the future of sjogren’s syndrome management globally.

• In July 2025, Novartis AG reported positive Phase II clinical trial results for an investigational biologic therapy targeting B-cell–mediated immune pathways in patients with moderate to severe sjogren’s syndrome. The study showed improvements in disease activity scores and symptom relief, highlighting growing interest in targeted immunomodulatory treatments for autoimmune conditions.
• In March 2025, Bristol Myers Squibb advanced its autoimmune research pipeline by initiating a multicenter clinical study to evaluate a novel immune pathway inhibitor for systemic manifestations associated with sjogren’s syndrome. The move underscores increasing pharmaceutical investment in disease-modifying therapies that go beyond symptomatic treatment to address significant unmet clinical needs in sjogren’s syndrome.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Test
  • By Drug Type
  • By Type
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - AbbVie Inc., Bausch + Lomb Corporation, F. Hoffmann-La Roche Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Sjogren’s Syndrome  Market Report Segment

By Test

• Blood Test
• Eye Test
• Imaging Test
• Biopsy

By Drug Type

• Pilocarpine
• Cyclosporine
• Hydroxychloroquine
• Immunosuppressive Agents

By Type

• Primary Sjogren’s Syndrome
• Secondary Sjogren’s Syndrome

Sjogren’s Syndrome  Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/sjogrens-syndrome-market